NCT06927570View on ClinicalTrials.gov

A Study of HS-20122 in Patients With Advanced Solid Tumors

PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

1,050

Participants

Timeline

Start Date

May 9, 2025

Primary Completion Date

January 31, 2028

Study Completion Date

June 30, 2028

Conditions
Advanced Solid Tumors
Interventions
DRUG

HS-20122（Phase 1a：Dose Escalation）

Intravenous (IV) administration of HS-20122 ; Participants will continue treatment until the end of the study in the absence of unacceptable toxicities and confirmed disease progression.

DRUG

HS-20122（Phase 1b：Dose Expansion ）

travenous (IV) administration of HS-20122 ; Participants will continue treatment until the end of the study in the absence of unacceptable toxicities and confirmed disease progression.

All Listed Sponsors
lead

Hansoh BioMedical R&D Company

INDUSTRY